StockData
Dermata Therapeutics, Inc. logo

Dermata Therapeutics, Inc. (DRMA) stock

DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$0.57−0.03 (-4.75%)

Close on Nov 17, 2026Market cap $2.29MP/E –Yield –

Dermata Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Dermata Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$8.08M. For fiscal 2025 it was -$7.80M. The highest annual figure on record is -$4.03M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.80M–
FY2024Dec 31, 2024-$11.16M–
FY2023Dec 31, 2023-$6.41M–
FY2022Dec 31, 2022-$8.83M–
FY2021Dec 31, 2021-$5.69M–
FY2020Dec 31, 2020-$4.03M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.42M–
Q1 FY2026Mar 31, 2026-$2.48M–
Q4 FY2025Dec 31, 2025-$1.37M–
Q3 FY2025Sep 30, 2025-$1.80M–
Q2 FY2025Jun 30, 2025-$2.69M–
Q1 FY2025Mar 31, 2025-$1.93M–
Q4 FY2024Dec 31, 2024-$2.91M–
Q3 FY2024Sep 30, 2024-$3.42M–
Q2 FY2024Jun 30, 2024-$2.13M–
Q1 FY2024Mar 31, 2024-$2.70M–
Q4 FY2023Dec 31, 2023-$1.15M–
Q3 FY2023Sep 30, 2023-$1.77M–
Q2 FY2023Jun 30, 2023-$1.84M–
Q1 FY2023Mar 31, 2023-$1.65M–
Q4 FY2022Dec 31, 2022-$1.83M–
Q3 FY2022Sep 30, 2022-$2.56M–
Q2 FY2022Jun 30, 2022-$1.84M–
Q1 FY2022Mar 31, 2022-$2.61M–
Q4 FY2021Dec 31, 2021-$1.80M–
Q3 FY2021Sep 30, 2021-$2.21M-139.4%
Q2 FY2021Jun 30, 2021-$903.21K–
Q1 FY2021Mar 31, 2021-$776.22K–
Q4 FY2020Dec 31, 2020-$7.52M–
Q3 FY2020Sep 30, 2020$5.62M–

More Dermata Therapeutics figures

See a number that looks wrong?